The development of neutralizing anti-VEGF antibodies has dramatically prolonged survival time in cancer patients, especially in patients with non-small cell lung cancer (NSCLC), glioblastoma, and ovarian cancer [126]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.